Overview

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Panitumumab